Associate professor at Shanghai Jiao Tong University, raised funds in four rounds within two years

Tushen Intelligence announced the completion of a ten-million-yuan-level RMB Angel + round of financing, jointly invested by the Shanghai Angel Association, with existing shareholder Chengmei Capital continuing to follow-on invest.

Wuxi Tushen Intelligence Artificial Intelligence Technology Co., Ltd. (hereinafter referred to as "Tushen Intelligence") recently announced the completion of a ten-million-yuan-level RMB Angel + round of financing.

It is reported that this round of financing for Tushen Intelligence was jointly invested by the Shanghai Angel Association, with existing shareholder Chengmei Capital continuing to follow-on invest. Tushen Intelligence said that it will further invest the financing funds in the R & D of the AI protein platform to continuously accelerate product innovation.

Four Rounds of Financing in Two Years

Founded in December 2023, Tushen Intelligence is a biotech company focusing on the field of artificial intelligence protein design. The company promotes scientific R & D with AI super-intelligent technology, which is mainly applied to the design and industrialization of high-value proteins and related products.

Tushen Intelligence is a typical academic startup. Its founder, Wang Yuguang, currently serves as an associate professor at the Institute of Natural Sciences of Shanghai Jiao Tong University, and also serves as a part-time associate professor at the Shanghai Artificial Intelligence Laboratory and the University of New South Wales, Sydney.

According to the official website of the Institute of Natural Sciences of Shanghai Jiao Tong University, Wang Yuguang's research interests cover artificial intelligence, applied mathematics and statistics, as well as the application of artificial intelligence in fields such as synthetic biology and protein design. He has published more than 100 papers in top international journals and conferences.

The core team of Tushen Intelligence brings together professionals in the fields of artificial intelligence and biotechnology. Most of the members are from well - known domestic and foreign universities and research institutions such as Shanghai Jiao Tong University, Johns Hopkins University, Tsinghua University, and the University of Cambridge, and have rich experience in the scientific research and industrialization of artificial intelligence.

Currently, Tushen Intelligence has established a scientific intelligent agent platform focusing on the biomedical field, which can realize the intelligent and automated antibody design, including the ProteinNova protein design AI scientist and the protein expression testing intelligent agent platforms. At the same time, based on domestic chip super-intelligent technology, it has independently developed multiple closed - source protein design models and deeply optimized a variety of vertical open - source SOTA models.

In terms of industrial application, Tushen Intelligence has made substantial progress. For example, in the affinity improvement of rabbit monoclonal antibodies, its results are better than the commercial antibodies of leading European pharmaceutical companies; in enzyme improvement, the activity of redox enzymes increased by 380% in the first round of AI design, and the activity of nucleases increased by 800%.

Reporters from the Venture Capital Daily noticed that Tushen Intelligence received a several - million - yuan angel round of financing jointly invested by Chengmei Capital and Photon Core Valley just three months after its establishment.

As of now, Tushen Intelligence has completed four rounds of financing. According to the data prediction of Cailian Press Venture Capital Connect - Zhizhong, taking September 2025 as the benchmark time, the predicted probability of financing in the next two years is 30.25%.

Reporters from the Venture Capital Daily noted that Xiamen Chengmei Digital Intelligence Empowerment Equity Investment Partnership under Chengmei Capital has participated in three rounds of financing of Tushen Intelligence in a row.

Pan Yangfa, a partner of Chengmei Capital, previously said that the institution has long been concerned about the empowerment of various industries by artificial intelligence technology. The team members of Tushen Intelligence have a compound background in artificial intelligence and biotechnology, with solid technology and forward - looking insights into the industry development. Since the launch of its AI protein general design platform, it has been recognized by leading domestic and foreign biomedical enterprises.

The Global AI + Protein Track is Developing Rapidly, with China Focusing on Industrialization

With the in - depth application of artificial intelligence technology, the global protein design market has shown a rapid development trend in recent years. Efficient and accurate protein design has become a competitive high - ground in new drug development, industrial enzyme catalysis, and biological material preparation.

According to market data statistics, currently, enterprises deploying in the field of AI proteins are mainly concentrated in China and the United States. Among them, China currently has about 30 AI protein - related enterprises, while there are 25 major companies overseas.

In terms of technical directions, these enterprises can be roughly divided into two categories. One category focuses on AI protein structure prediction and design, and the other focuses on AI proteomics. From the perspective of establishment background, whether at home or abroad, the core technologies of the vast majority of enterprises are traced back to the laboratories of universities or research institutions.

In terms of technical routes, Chinese and overseas enterprises also have different development paths in the AI protein track.

Overseas enterprises mainly focus on breakthroughs in basic large models, providing a "scientific research brain" for the AI + protein field. For example, AlphaFold, an artificial intelligence program based on deep learning developed by DeepMind in the UK, focuses on predicting the three - dimensional structure of proteins through amino acid sequences and is regarded as a landmark tool for solving the "protein folding problem" that has puzzled the biological community for 50 years.

Chinese enterprises are committed to building the "industrial body" in the AI + protein field, emphasizing the practicality of technology and industrialization efficiency. For example, companies such as MoleculeMind have launched the industrial - grade AI protein design platform "MoleculeOS", which significantly lowers the usage threshold and enables the "one - click design" of proteins with specific functions. At present, Tushen Intelligence started relatively late.

Generally speaking, AI protein design technology shows broad application prospects in many important fields such as new drug R & D, precision medicine, and synthetic biology. However, this field still faces challenges such as data quality, model interpretability, and high costs of wet - lab verification. Whether it can achieve standardized and large - scale application in the industrialization closed - loop will also be the key for enterprises to move from technology R & D to commercial implementation.

Special Statement: The content of this article is for reference only and does not constitute investment advice. Investors shall bear the risks of their own operations.

This article is from the WeChat public account "Venture Capital Daily", author: Li Jiayi, published by 36Kr with authorization.